Tesamorelin is intended as a treatment for excess abdominal fat in HIV-infected patients with lipodystrophy.
Earlier in December 2010, Theratechnologies has given license to an affiliate of Sanofi to commercialize for tesamorelin in Latin America, Africa and the Middle East.
Theratechnologies president and CEO John-Michel Huss said this is the first regulatory application for tesamorelin in Latin America.